Suppr超能文献

在博茨瓦纳流行的新冠病毒重组毒株的基因组流行病学与免疫逃逸

Genomic epidemiology and immune escape of SARS-CoV-2 recombinant strains circulating in Botswana.

作者信息

Choga Wonderful T, Gobe Irene, Seru Kedumetse, Maruapula Dorcas, Ndlovu Nokuthula S, Zuze Boitumelo J L, Motshosi Patience, Matsuru Teko, Sabone Phenyo, Yu Xiaoyu, Blackard Jason T, San James E, Makhema Joseph, Gaseitsiwe Simani, Moyo Sikhulile

机构信息

Botswana Harvard Health Partnership, Gaborone, Botswana.

School of Allied Health Sciences, Faculty of Health Sciences, Gaborone, Botswana.

出版信息

IJID Reg. 2024 Nov 2;13:100484. doi: 10.1016/j.ijregi.2024.100484. eCollection 2024 Dec.

Abstract

OBJECTIVES

We characterized the molecular and mutational landscape of SARS-CoV-2 recombinant strains in Botswana.

METHODS

We performed genomic, phylogenetic, and immunoinformatic analyses of 5254 near-complete genomes from 2020 to 2023. We assessed the presence of mutations of interested (MutOI) that may be associated with immune escape .

RESULTS

We observed a few recombinant strains in Botswana, with the majority being descendants of Omicron (XBB*), except for XV and XM. Most recombinant sequences corresponded to transmission clusters. Most recombination events occurred within the receptor-binding domain (RDB) of the spike (S) protein. We identified 16 MutOI among different proteins, with the majority occurring at a very low global prevalence (<4.8 × 10⁵). We also observed S:Q474K, a MutOI in the RBD, that was predicted to escape human leukocyte antigen class I-mediated immune responses. Molecular surveillance is vital to inform early detection and response to potential variants with heightened immune and vaccine breakthrough properties.

CONCLUSIONS

These results underscore the need for continued molecular surveillance to map the evolutionary landscape of SARS-CoV-2.

摘要

目的

我们对博茨瓦纳的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)重组毒株的分子和突变情况进行了特征分析。

方法

我们对2020年至2023年的5254个近乎完整的基因组进行了基因组、系统发育和免疫信息学分析。我们评估了可能与免疫逃逸相关的感兴趣突变(MutOI)的存在情况。

结果

我们在博茨瓦纳观察到了一些重组毒株,除XV和XM外,大多数是奥密克戎(XBB*)的后代。大多数重组序列对应于传播簇。大多数重组事件发生在刺突(S)蛋白的受体结合域(RBD)内。我们在不同蛋白质中鉴定出16种MutOI,其中大多数在全球流行率非常低(<4.8×10⁵)的情况下出现。我们还观察到RBD中的一种MutOI,即S:Q474K,预计它会逃避人类白细胞抗原I类介导的免疫反应。分子监测对于早期发现和应对具有增强免疫和疫苗突破特性的潜在变异至关重要。

结论

这些结果强调了持续进行分子监测以描绘SARS-CoV-2进化情况的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ed4/11636131/b7f8c8b781f1/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验